203513-49-9

Basic information

• Product Name: 4-phenylpyrrolo[1,2-a]quinoxaline-2-carboxaldehyde
• Synonyms: 4-phenylpyrrolo[1,2-a]quinoxaline-2-carboxaldehyde
• CAS NO: 203513-49-9
• Molecular Weight: 272.306
• Mol File: 203513-49-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-phenylpyrrolo[1,2-a]quinoxaline-2-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-phenylpyrrolo[1,2-a]quinoxaline-2-carboxaldehyde(203513-49-9)
• EPA Substance Registry System: 4-phenylpyrrolo[1,2-a]quinoxaline-2-carboxaldehyde(203513-49-9)

Safety Data

• Hazardous Substances Data: 203513-49-9(Hazardous Substances Data)

Upstream product

• 579-07-7 1-Phenylpropane-1,2-dione 
• 210223-15-7 ethyl 4-phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate 
• 95-54-5 1,2-diamino-benzene 
• 10130-23-1 2-methyl-3-phenylquinoxaline 
• 210223-17-9 (4-Phenyl-pyrrolo[1,2-a]quinoxalin-2-yl)-methanol 

Downstream Products

• 203513-46-6 ethyl 4-methyl-3-(4'-phenylpyrrolo[1,2-a]quinoxalin-2'-yl)-1H-pyrrole-2-carboxylate 
• 326500-23-6 4-phenyl-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-pyrrolo[1,2-a]quinoxaline 
• 326500-22-5 2-[4-(2-methoxy-phenyl)-piperazin-1-ylmethyl]-4-phenyl-pyrrolo[1,2-a]quinoxaline 
• 326500-24-7 2-[4-(4-chloro-phenyl)-piperazin-1-ylmethyl]-4-phenyl-pyrrolo[1,2-a]quinoxaline 
• 326500-21-4 4-phenyl-2-(4-phenyl-piperazin-1-ylmethyl)-pyrrolo[1,2-a]quinoxaline 
• 326500-26-9 4-phenyl-2-(4-phenyl-3,6-dihydro-2H-pyridin-1-ylmethyl)-pyrrolo[1,2-a]quinoxaline 
• 203513-50-2 2-(2-nitropropenyl)-4-phenylpyrrolo[1,2-a]quinoxaline 

Relevant articles and documents

Synthesis of new 2-(aminomethyl)-4-phenylpyrrolo[1,2-a]-quinoxalines and their preliminary in-vivo central dopamine antagonist activity evaluation in mice

In the search for antipsychotic agents that are not associated with extrapyramidal side effects, efforts have been focused on finding selective D4-receptor antagonists and investigating their pharmacology. Our laboratory has developed a synthesis program for new pyrroloquinoxalines with therapeutic potential. We have described the synthesis of some new pyrroloquinoxalines with substituted arylpiperazino or aryltetrahydropyrido chain at position 3 of the quinoxaline ring (2-(4-phenylpiperazin-1-ylmethyl)-4-phenylpyrrolo[1,2-a]quinoxalinium oxalate (3a), 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]-4-phenylpyrrolo[1,2-a]quinoxal inium oxalate (3b), 2-[4-(3-trifluoromethylphenyl)piperazin-1-ylmethyl]-4-phenylpyrrolo[1,2-a]quinox alinium oxalate (3c), 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-4-phenylpyrrolo[1,2-a]quinoxaliniumox alate (3d), 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-4-phenylpyrrolo[1,2-a]quinoxalinium oxalate (3e), and 2-(4-phenyl-1,2,3,6-tetrahydropyridin-1-ylmethyl)-4-phenylpyrrolo[1,2-a]quinoxal inium oxalate (3f)). A preliminary pharmacological study of these products was conducted using climbing behaviour induced by apomorphine (2.5 mg kg-1, s.c.) in mice. The derivatives were administered intraperitoneally 30 min before apomorphine. Haloperidol, chlorpromazine and clozapine were used as references. Among this series, 3b, 3c and 3f revealed a central dopamine antagonist activity. The most active derivative was 3b, which exhibited a profile relatively close to clozapine.

Synthesis of new pyrrolo[l,2-a]quinoxalines: Potential non-peptide glucagon receptor antagonists

Synthesis of new pyrrolo[1,2-a]quinoxaline derivatives was achieved starting from various nitroanilines or orthophenyle-nediamines. Their affinity towards glucagon receptors was evaluated. Elsevier, Paris.